Long-term Follow-up Results of a Multi-institutional Phase 2 Study of Concurrent Chemoradiation Therapy for Locally Advanced Cervical Cancer in East and Southeast Asia
- Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama (Japan)
- Gunma University Heavy Ion Medical Center, Gunma University, Gunma (Japan)
- Division of Radiation Oncology, Department of Radiology, Siriraj Hospital, Faculty of Medicine, Mahidol University, Bangkok (Thailand)
- School of Radiation Medicine and Public Health, Soochow University, Soochow (China)
- Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Soochow (China)
- Department of Radiotherapy and Oncology, Hospital Umum Sarawak, Kuching (Malaysia)
- Department of Radiation Oncology, St. Luke's Medical Center, Quezon City, the Philippines (Philippines)
- Department of Obstetrics and Gynecology, Dr Jose R. Reyes Memorial Medical Center, Manila, the Philippines (Philippines)
- Department of Radiation Oncology, Korea Cancer Center Hospital, Seoul (Korea, Republic of)
- Department of Breast and Gynecology Radiotherapy, National Cancer Institute, Hanoi (Viet Nam)
- Department of Radiation Therapy, Faculty of Medicine, University of Indonesia, Dr Cipto Mangunkusumo General Hospital, Jakarta (Indonesia)
- Division of Radiotherapy, Dr Soetomo General Hospital, Surabaya (Indonesia)
- National Institute of Radiological Sciences of Japan, Chiba (Japan)
- Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma (Japan)
Purpose: To report the long-term survival and toxicity of a multi-institutional phase 2 study of concurrent chemoradiation therapy (CCRT) for locally advanced cervical cancer in east and southeast Asia. Methods and Materials: Ten institutions from 8 Asian countries participated in the study. Between April 2003 and March 2006, 120 patients (60 with bulky stage IIB and 60 with stage IIIB) were treated with CCRT. Radiation therapy consisted of pelvic external beam radiation therapy and either high-dose-rate or low-dose-rate intracavitary brachytherapy. Five cycles of weekly cisplatin (40 mg/m{sup 2}) were administered during the course of radiation therapy. Treatment results were evaluated by the rates of local control, overall survival, and late toxicities. Results: Median follow-up was 63.7 months, and the follow-up rate at 5 years was 98%. The 5-year local control and overall survival rates for all patients were 76.8% and 55.1%, respectively. The 5-year rates of major late toxicities of the rectum and bladder were 7.9% and 0%, respectively. Conclusions: The long-term results have suggested that CCRT is safe and effective for patients with locally advanced cervical cancer in east and southeast Asia. However, further efforts are needed to improve overall survival.
- OSTI ID:
- 22267859
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 87, Issue 1; Other Information: Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Accelerated Hyperfractionated Radiotherapy for Cervical Cancer: Multi-Institutional Prospective Study of Forum for Nuclear Cooperation in Asia Among Eight Asian Countries
High-dose-rate brachytherapy in uterine cervical carcinoma